No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US Stock MarketDetailed Quotes
RVNC Revance Therapeutics
- 3.090
- +0.030+0.98%
Close Jan 3 16:00 ET
- 3.090
- 0.0000.00%
Post 19:54 ET
322.56MMarket Cap-1.61P/E (TTM)
3.090High3.050Low1.27MVolume3.050Open3.060Pre Close3.92MTurnover1.33%Turnover RatioLossP/E (Static)104.39MShares7.58752wk High-1.98P/B296.43MFloat Cap2.30052wk Low--Dividend TTM95.93MShs Float42.410Historical High--Div YieldTTM1.31%Amplitude2.300Historical Low3.080Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Barclays Maintains Equal-Weight on Revance Therapeutics, Lowers Price Target to $3
Analysts Offer Insights on Healthcare Companies: Revance Therapeutics (RVNC) and Neurocrine (NBIX)
Revance Therapeutics Ticks Higher as Holder Says Crown Deal Undervalues Company
Key Deals for the Week: Patterson, Hershey & Mondelez, AIG & Nippon and More
Shareholder Alert: Ademi LLP Investigates Whether Revance Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
Revance Therapeutics Board Recommends Stockholders Tender Shares to Crown Laboratories
Heat List
US
Overall
Symbol
Price
% Chg
No Data